Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 46 to 60 of 104 results for melanoma

  1. Vitamin D supplementation: In people with stage I to III melanoma does vitamin D supplementation improve overall survival? This should be investigated in a placebo controlled randomised trial. Secondary outcomes should include disease specific survival and toxicity, including the development of renal stones and hypercalcaemia.

    Question Vitamin D supplementation: In people with stage I to III melanoma does vitamin D supplementation improve overall survival? This...

    Research recommendation
    Published
    4 August 2022

  2. NICE considered that more research is needed to establish the treatment sequence for vemurafenib and ipilimumab in patients who have BRAF V600 mutation-positive melanoma.

    vemurafenib and ipilimumab in patients who have BRAF V600 mutation-positive melanoma. Any explanatory notes(if applicable) This may...

    Research recommendation
    Published
    9 June 2015

  3. Medical technologies guidance

    Our medical technologies guidance evaluates new, innovative medical devices and diagnostics.

  4. Sun Safe Schools Accreditation – National intervention programme

    of Karen Clifford (the 'KC' in Skcin) who lost her courageous battle to melanoma, aged 61. NICE guideline Sunlight exposure: risks and...

    Shared learning
    Last updated
    27 April 2021

  5. Ixekizumab for treating moderate to severe plaque psoriasis (TA442)

    Evidence-based recommendations on ixekizumab (Taltz) for moderate to severe plaque psoriasis in adults.

    Technology appraisal guidance
    Published
    26 April 2017
    View recommendations

    Sections for TA442

  6. Bifikafusp alfa–onfekafusp alfa for neoadjuvant treatment of 3B or 3C resectable melanoma [ID6384]

      Status ...

    Technology appraisal guidance
    Topic selection

  7. What proportion of people with melanoma who are referred into secondary care under the 2 week wait rule, have equivocal moles that are excised and have equivocal moles that are monitored?

    Recommendation ID DG19/2 Question What proportion of people with melanoma who are referred into secondary care under the 2 week wait...

    Research recommendation
    Published
    12 January 2016

  8. What is the impact of using the VivaScope 1500 and 3000 imaging systems in the clinical workflow of melanoma and basal cell carcinoma assessment in secondary care in England, particularly on excision rates, diagnostic accuracy, health related quality of life and associated NHS costs?

    the VivaScope 1500 and 3000 imaging systems in the clinical workflow of melanoma and basal cell carcinoma assessment in secondary care...

    Research recommendation
    Published
    12 January 2016

  9. Electrochemotherapy for the treatment of malignant melanoma

    Discontinued [GID-IP1041]

    Interventional procedures guidance
    Discontinued

  10. Nivolumab for previously treated advanced renal cell carcinoma (TA417)

    Evidence-based recommendations on nivolumab (Opdivo) for previously treated advanced renal cell carcinoma in adults.

    Technology appraisal guidance
    Published
    23 November 2016
    View recommendations

    Sections for TA417

  11. Monitoring and response biomarkers: Can biomarkers accurately classify recurrence, progression and response to treatment?

    analysis of melanoma tissue samples. Full details of the evidence and the committee's discussion are in evidence review A: genetic...

    Research recommendation
    Published
    4 August 2022

  12. Cancer: stage at diagnosis recorded (IND2)

    This indicator covers the proportion of new cases of cancer with stage at diagnosis recorded. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG02

    Network / system level indicators
    Last updated
    4 November 2020

  13. Pembrolizumab with lenvatinib for previously treated advanced or recurrent endometrial cancer (TA904)

    Evidence-based recommendations on pembrolizumab (Keytruda) with lenvatinib (Lenvima) for treating advanced or recurrent endometrial cancer in adults.

    Technology appraisal guidance
    Published
    21 June 2023
    View recommendations

    Sections for TA904

  14. Pembrolizumab with epacadostat for untreated malignant melanoma [ID1423]

    Discontinued [GID-TA10330]

    Technology appraisal guidance
    Discontinued

  15. Accreditation

    NICE guidance accredited decisions - status and term dates of NICE accredited guidance producers.